MicroRNA as a prognostic biomarker for survival in childhood acute lymphoblastic leukemia: a systematic review
Tóm tắt
Recent studies suggest abnormal microRNA (miRNA) expression may have potential prognostic value in childhood acute lymphoblastic leukemia (ALL). In this systematic review, we searched different databases (PubMed, ASH, ASCO, and SIOP) for studies published from 2008 to 2018 that evaluated the prognostic impact of miRNAs in childhood ALL. We also used DIANA-miRPath v3.0 to further characterize the functional role of the significant prognostic miRNAs identified in our systematic review. Here we evaluate 15 studies with a total of 38 different miRNAs and 1545 children with B-cell ALL (B-ALL) or T-cell ALL (T-ALL) recruited over approximately 3 decades (1984–2016) with different treatment protocols and ethnicities. Out of the 15 studies examined, 14 reported 32 dysregulated miRNAs with significant prognostic impact in pediatric ALL patients. Only one Brazilian study reported no significant prognostic effect of 7 miRNAs, while the seventh miRNA (miR-100) showed prognostic significance in a Chinese study. Using DIANA-TarBase v7.0 of DIANA-miRPath v3.0, pathway enrichment analysis revealed 25 miRNAs modulated 24 molecular pathways involved in cancer development. To remove the effect of salvage therapy, 9 studies carried out multivariate cox regression analysis for both relapse-free survival and disease-free survival to develop a panel of 23 miRNAs acting as independent prognostic biomarkers. To enhance the clinical application, utility, and validity of the miRNAs discussed here, their potential prognostic value should be confirmed in larger cohort studies within different ethnicities and different ALL protocols adjusted for other contemporary validated prognostic factors in childhood ALL.
Tài liệu tham khảo
Kato, M., & Manabe, A. (2018). Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatrics International, 60(1), 4–12. https://doi.org/10.1111/ped.13457.
Hudson, M. M., Link, M. P., & Simone, J. V. (2014). Milestones in the curability of pediatric cancers. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 32(23), 2391–2397. https://doi.org/10.1200/JCO.2014.55.6571.
Raetz, E. A., & Bhatla, T. (2012). Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematology. American Society of Hematology. Education Program, 2012, 129–136. https://doi.org/10.1182/asheducation-2012.1.129.
Hanna, J., Hossain, G. S., & Kocerha, J. (2019). The potential for microRNA therapeutics and clinical research. Frontiers in Genetics, 10, 478. https://doi.org/10.3389/fgene.2019.00478.
Petrescu, G. E. D., Sabo, A. A., Torsin, L. I., Calin, G. A., & Dragomir, M. P. (2019). MicroRNA based theranostics for brain cancer: basic principles. Journal of Experimental & Clinical Cancer Research, 38(1), 231. https://doi.org/10.1186/s13046-019-1180-5.
Fan, R., Xiao, C., Wan, X., Cha, W., Miao, Y., Zhou, Y., Qin, C., Cui, T., Su, F., & Shan, X. (2019). Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics. RNA Biology, 16(6), 707–718. https://doi.org/10.1080/15476286.2019.1593094.
Bonneau, E., Neveu, B., Kostantin, E., Tsongalis, G. J., & De Guire, V. (2019). How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. EJIFCC, 30(2), 114–127. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/31263388
Vlachos, I. S., Zagganas, K., Paraskevopoulou, M. D., Georgakilas, G., Karagkouni, D., Vergoulis, T., Dalamagas, T., & Hatzigeorgiou, A. G. (2015). DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Research, 43(W1), W460–W466. https://doi.org/10.1093/nar/gkv403.
Yan, J., Jiang, N., Huang, G., Tay, J. L.-S., Lin, B., Bi, C., et al. (2013). Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 163(1), 93–103. https://doi.org/10.1111/bjh.12489.
Mosakhani, N., Sarhadi, V. K., Usvasalo, A., Karjalainen-Lindsberg, M.-L., Lahti, L., Tuononen, K., … Knuutila, S. (2012). MicroRNA profiling in pediatric acute lymphoblastic leukemia: novel prognostic tools. Leukemia & Lymphoma. England. doi:https://doi.org/10.3109/10428194.2012.685731
Avigad, S., Verly, I. R. N., Lebel, A., Kordi, O., Shichrur, K., Ohali, A., et al. (2016). miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia. Genes, Chromosomes & Cancer, 55(4), 328–339. https://doi.org/10.1002/gcc.22334.
Han, B.-W., Feng, D.-D., Li, Z.-G., Luo, X.-Q., Zhang, H., Li, X.-J., Zhang, X. J., Zheng, L. L., Zeng, C. W., Lin, K. Y., Zhang, P., Xu, L., & Chen, Y.-Q. (2011). A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Human Molecular Genetics, 20(24), 4903–4915. https://doi.org/10.1093/hmg/ddr428.
Schotte, D., de Menezes, R. X., Moqadam, F. A., Khankahdani, L. M., Lange-Turenhout, E., Chen, C., et al. (2011). MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica, 96(5), 703–711. https://doi.org/10.3324/haematol.2010.026138.
de Oliveira, J. C., Scrideli, C. A., Brassesco, M. S., Morales, A. G., Pezuk, J. A., Queiroz, R. d. P., et al. (2012). Differential MiRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leukemia Research, 36(3), 293–298. https://doi.org/10.1016/j.leukres.2011.10.005.
Organista-Nava, J., Gómez-Gómez, Y., Illades-Aguiar, B., Del Carmen Alarcón-Romero, L., Saavedra-Herrera, M. V., Rivera-Ramírez, A. B., et al. (2015). High miR-24 expression is associated with risk of relapse and poor survival in acute leukemia. Oncology Reports, 33(4), 1639–1649. https://doi.org/10.3892/or.2015.3787.
Li, X. J., Luo, X. Q., Han, B. W., Duan, F. T., Wei, P. P., & Chen, Y. Q. (2013). MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. British Journal of Cancer, 109(8), 2189–2198. https://doi.org/10.1038/bjc.2013.562.
Labib, H. A., Elantouny, N. G., Ibrahim, N. F., & Alnagar, A. A. (2017). Upregulation of microRNA-21 is a poor prognostic marker in patients with childhood B cell acute lymphoblastic leukemia. Hematology (Amsterdam, Netherlands), 22(7), 392–397. https://doi.org/10.1080/10245332.2017.1292204.
Piatopoulou, D., Avgeris, M., Drakaki, I., Marmarinos, A., Xagorari, M., Baka, M., Pourtsidis, A., Kossiva, L., Gourgiotis, D., & Scorilas, A. (2018). Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. Annals of Hematology, 97(7), 1169–1182. https://doi.org/10.1007/s00277-018-3292-y.
Piatopoulou, D., Avgeris, M., Marmarinos, A., Xagorari, M., Baka, M., Doganis, D., Kossiva, L., Scorilas, A., & Gourgiotis, D. (2017). miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. British Journal of Cancer, 117(6), 801–812. https://doi.org/10.1038/bjc.2017.256.
Kaddar, T., Chien, W. W., Bertrand, Y., Pages, M. P., Rouault, J. P., Salles, G., et al. (2009). Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. Leukemia Research, 33(9), 1217–1223. https://doi.org/10.1016/j.leukres.2008.12.015.
Agirre, X., Vilas-Zornoza, A., Jimenez-Velasco, A., Martin-Subero, J. I., Cordeu, L., Garate, L., et al. (2009). Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Research, 69(10), 4443–4453. https://doi.org/10.1158/0008-5472.CAN-08-4025.
Sirugo, G., Williams, S. M., & Tishkoff, S. A. (2019). The missing diversity in human genetic studies. Cell, 177(1), 26–31. https://doi.org/10.1016/j.cell.2019.02.048.
Cooper, S. L., & Brown, P. A. (2015). Treatment of pediatric acute lymphoblastic leukemia. Pediatric Clinics of North America, 62(1), 61–73. https://doi.org/10.1016/j.pcl.2014.09.006.
Schmidt, S., Rainer, J., Ploner, C., Presul, E., Riml, S., & Kofler, R. (2004). Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death and Differentiation, 11(S1), S45–S55. https://doi.org/10.1038/sj.cdd.4401456.
Groninger, E., Meeuwsen-De Boer, G., De Graaf, S., Kamps, W., & De Bont, E. (2002). Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species? International Journal of Oncology, 21(6), 1339–1345. https://doi.org/10.3892/ijo.21.6.1339.
Richardson, D. S., & Johnson, S. A. (1997). Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. Blood Reviews, 11(4), 201–23. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9481450.
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., Rassenti, L., Alder, H., Volinia, S., Liu, C. G., Kipps, T. J., Negrini, M., & Croce, C. M. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences, 102(39), 13944–13949. https://doi.org/10.1073/pnas.0506654102.
Jing, D., Bhadri, V. A., Beck, D., Thoms, J. A. I., Yakob, N. A., Wong, J. W. H., et al. (2015). Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood, 125(2), 273–283. https://doi.org/10.1182/blood-2014-05-576470.
Zhang, H., Luo, X.-Q., Zhang, P., Huang, L.-B., Zheng, Y.-S., Wu, J., et al. (2009). MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One, 4(11), e7826. https://doi.org/10.1371/journal.pone.0007826.
Mei, Y., Gao, C., Wang, K., Cui, L., Li, W., Zhao, X., Liu, F., Wu, M., Deng, G., Ding, W., Jia, H., & Li, Z. (2014). Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Science, 105(4), 463–472. https://doi.org/10.1111/cas.12370.
Mei, Y., Li, Z., Zhang, Y., Zhang, W., Hu, H., Zhang, P., Wu, M., & Huang, D. (2017). Low miR-210 and CASP8AP2 expression is associated with a poor outcome in pediatric acute lymphoblastic leukemia. Oncology Letters, 14(6), 8072–8077. https://doi.org/10.3892/ol.2017.7229.